171 related articles for article (PubMed ID: 4633977)
1. Trial of a serogroup A meningococcus polysaccharide vaccine in Nigeria.
Sanborn WR; Bencić Z; Cvjetanović B; Gotschlich EC; Pollock TM; Sippel JE
Prog Immunobiol Stand; 1971; 5():497-505. PubMed ID: 4633977
[No Abstract] [Full Text] [Related]
2. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria.
Wahdan MH; Sallam SA; Hassan MN; Abdel Gawad A; Rakha AS; Sippel JE; Hablas R; Sanborn WR; Kassem NM; Riad SM; Cvjetanović B
Bull World Health Organ; 1977; 55(6):645-51. PubMed ID: 413639
[TBL] [Abstract][Full Text] [Related]
3. A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A.
Erwa HH; Haseeb MA; Idris AA; Lapeyssonnie L; Sanborn WR; Sippel JE
Bull World Health Organ; 1973; 49(3):301-5. PubMed ID: 4211056
[TBL] [Abstract][Full Text] [Related]
4. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine.
Wahdan MH; Rizk F; el-Akkad AM; el-Ghoroury AA; Hablas R; Girgis NI; Amer A; Boctar W; Sippel JE; Gotschlich EC; Triau R; Sanborn WR; Cvjetanović B
Bull World Health Organ; 1973 Jun; 48(6):667-73. PubMed ID: 4206451
[TBL] [Abstract][Full Text] [Related]
5. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
Jennings HJ
Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
[No Abstract] [Full Text] [Related]
6. [Survey on efficacy of inoculating purified polysaccharide vaccines as an emergency measure in preventing epidemic meningitis].
Xu CH
Zhonghua Liu Xing Bing Xue Za Zhi; 1982 Dec; 3(6):328-30. PubMed ID: 6821030
[No Abstract] [Full Text] [Related]
7. [Preventive effectiveness of an urgent mass vaccination with purified meningococcal polysaccharide vaccine observed during a meningitis epidemic].
Wu C
Zhonghua Liu Xing Bing Xue Za Zhi; 1985 Dec; 6(6):344-6. PubMed ID: 3938683
[No Abstract] [Full Text] [Related]
8. [Vaccines against Neisseria meningitidis].
Ferrón L; Criado MT; Ferreirós CM
Enferm Infecc Microbiol Clin; 1992 May; 10(5):296-301. PubMed ID: 1391002
[No Abstract] [Full Text] [Related]
9. Control of epidemic meningococcal meningitis by mass vaccination.
Mohammed I; Zaruba K
Lancet; 1981 Jul; 2(8237):80-2. PubMed ID: 6113451
[No Abstract] [Full Text] [Related]
10. Control of meningococcal infection in the African meningitis belt by selective vaccination.
Greenwood BM; Wali SS
Lancet; 1980 Apr; 1(8171):729-32. PubMed ID: 6103155
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
Peltola H; Mäkelä H; Käyhty H; Jousimies H; Herva E; Hällström K; Sivonen A; Renkonen OV; Pettay O; Karanko V; Ahvonen P; Sarna S
N Engl J Med; 1977 Sep; 297(13):686-91. PubMed ID: 408682
[TBL] [Abstract][Full Text] [Related]
12. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
[TBL] [Abstract][Full Text] [Related]
13. Editorial retrospective. Meningococcal A and other polysaccharide vaccines. A five-year progress report.
Lepow ML; Gold R
N Engl J Med; 1983 May; 308(19):1158-60. PubMed ID: 6403865
[No Abstract] [Full Text] [Related]
14. [Serogroup A N. meningitidis polysaccharide vaccine and serogroup A N. meningitidis carrier state (author's transl)].
Bencić Z; Madarić D; Manhalter T; John V; Amsel V; Weisglass H
Lijec Vjesn; 1978 Nov; 100(11):706-7. PubMed ID: 107385
[No Abstract] [Full Text] [Related]
15. Safety of meningococcal polysaccharide vaccine serogroup "A" (Pilot Study).
Bahl MR
Med J Zambia; 1975 Dec-1976 Jan; 9(6):166. PubMed ID: 818845
[TBL] [Abstract][Full Text] [Related]
16. Who should be given meningococcal vaccine?
Lancet; 1978 Dec; 2(8101):1185-6. PubMed ID: 82146
[No Abstract] [Full Text] [Related]
17. [Application of SP-RIA in the antibody surveillance and serologic diagnosis of epidemic cerebrospinal meningitis].
Chen X
Zhonghua Liu Xing Bing Xue Za Zhi; 1993 Dec; 14(6):366-70. PubMed ID: 8156584
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
Dashefsky B; Wald E; Guerra N; Byers C
Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
[TBL] [Abstract][Full Text] [Related]
19. Contemporary trends in conjugate vaccine development.
Cruse JM; Lewis RE
Contrib Microbiol Immunol; 1989; 10():1-10. PubMed ID: 2510970
[No Abstract] [Full Text] [Related]
20. Response of children to Neisseria meningitidis polysaccharide vaccines.
Monto AS; Brandt BL; Artenstein MS
J Infect Dis; 1973 Apr; 127(4):394-400. PubMed ID: 4632878
[No Abstract] [Full Text] [Related]
[Next] [New Search]
